Search clinical trials for: NNC0113-6861

Total 137 results

Novo Nordisk A/S

Completed

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Type 2 Diabetes | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Spain, Hungary, Serbia, Bulgaria, Poland, Russian Federation, Latvia
Novo Nordisk A/S

Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Russian Federation, Germany
Novo Nordisk A/S

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

Serbia, Hungary, Poland, United States
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Germany, Denmark
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Diabetes Mellitus, Type 2

Japan
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Novo Nordisk A/S

Recruiting

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Non-alcoholic Steatohepatitis (NASH)

Germany
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

Overweight and Obesity

China
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Xiangya Hospital of Central South University

Completed

Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013

Gastrointestinal Cancer

China
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Non-alcoholic Fatty Liver Disease

China
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Korea, Republic of, India, Australia, Canada, Japan, South Africa
Novo Nordisk A/S

Completed

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Bayer

Completed

Contrast-enhanced MRI in Children 2 Months to <2 Years

Magnetic Resonance Imaging

United States, Germany
Novo Nordisk A/S

Recruiting

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Healthy Volunteers | Hepatic Impairment

Germany, Poland, Slovakia
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Recruiting

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Behaves in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function

Hepatic Impairment

Germany, Slovakia
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, Sweden
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

France, Israel, Austria, Spain, Switzerland, North Macedonia, Norway, Slovenia, Belgium, Sweden
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Narcolepsy Type 1

Spain, Japan, France, Germany, United States, Norway, Netherlands, Finland, Switzerland, Australia, Italy, Sweden

3

Subscribe